CervoMed
CRVOCRVO · Stock Price
Historical price data
Overview
CervoMed is a clinical-stage biotech focused on developing treatments for neurodegenerative diseases by targeting neuroinflammation-induced synaptic dysfunction, a reversible early-stage pathology. The company's core achievement is positive Phase 2b data for neflamapimod in Dementia with Lewy Bodies (DLB) and alignment with the FDA on a Phase 3 trial design. Its strategy employs a biomarker-informed, precision medicine approach to treat patients at earlier disease stages without significant co-pathology, aiming to demonstrate disease modification where current therapies offer only symptomatic relief.
Technology Platform
Platform centered on inhibition of p38 alpha kinase to reverse neuroinflammation-induced synaptic dysfunction, utilizing a biomarker-informed (plasma pTau181) precision medicine approach for patient selection.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Neflamapimod + Placebo | Dementia With Lewy Bodies | Phase 2 | |
| Neflamapimod + Placebo | Moderate to Severe Acute Ischaemic Stroke | Phase 2 | |
| neflamapimod | Dementia With Lewy Bodies (DLB) | Phase 2 | |
| Neflamapimod + Placebo | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
In DLB, neflamapimod faces limited direct competition from disease-modifying therapies, competing mainly with off-label symptomatic care. Its primary differentiation is its oral, synaptic-targeting mechanism and biomarker strategy. Broader competition exists from other neuroinflammation-targeting approaches in neurodegeneration.